CAPD is a second-class treatment.
D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D007676:Kidney Failure, Chronic / Q000628:therapy*; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000209:etiology*; D012306:Risk
D007375:Interleukin-1